A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors
NCT04991740
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
39
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
JNJ-78306358
Sponsor
Janssen Research & Development, LLC